Table I.
Inhibition of SIV, SHIV and HIV-1 Replication by CMPD 167 In Vitro
| Virus | PBMC type |
Donor | IC50 | Max Inhibition |
|---|---|---|---|---|
| nM | % | |||
| SIVmac251 | macaque | A | 130 | 91 |
| B | 85 | 77 | ||
| C | 8.0 | 100 | ||
| D | 36 | 96 | ||
| E | 0.47 | 100 | ||
| SIVB670 | macaque | B | 9.3 | 55 |
| C | 5.3 | 98 | ||
| SHIV-162P4 | macaque | A | 61 | 86 |
| B | 3.4 | 100 | ||
| C | 5.2 | 100 | ||
| F | 30 | 100 | ||
| SHIV-89.6P | macaque | G | >10,000 | – |
| H | >10,000 | – | ||
| SHIV-162P4 | human | I | 0.030 | 100 |
| J | 0.24 | 98 | ||
| HIV-1 JR-FL | human | I | 0.27 | 100 |
| J | 0.20 | 97 | ||
| HIV-1 CC1/85 | human | I | 0.31 | 100 |
| J | 0.15 | 100 |
IC50 values derived from individual experiments using PBMC from different uninfected macaques (A–H ) or humans (I and J) are presented, along with the maximum percentage inhibition achieved with higher concentrations of CMPD 167 (up to 10 μM). Macques A–H do not correspond to animals described in Figs. 2–4.